CONSTELLATION PHARMACEUTICALS, INC. Inactive Instrument
Constellation Pharmaceuticals, Inc.
Equities
CNST
US2103731061
Biotechnology & Medical Research
Presenter SpeechAndrew Berens (Analysts)Good afternoon, everyone. It's Day 3 of the SVB Leerin...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.91% | 111B | |
| +11.42% | 105B | |
| -12.93% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.29% | 16.96B | |
| +2.44% | 13.7B | |
| +35.95% | 12.45B |
